Tomas Kiselak serves as Executive at Dianthus Therapeutics, Inc. /DE/, where they oversee executive responsibilities. Since joining the company, Tomas Kiselak has executed 8 insider transactions totaling $1.1M, demonstrating a bullish approach to their equity position. Their most recent transaction on Sep 17, 2025 involved receiving (via award) 333,340 shares valued at $5.0M.
Tomas Kiselak currently holds 1,131,954 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Tomas Kiselak has been a net buyer of DNTH stock. They have purchased $1.1M and sold $0 worth of shares.
Tomas Kiselak's most recent insider trade was on Sep 17, 2025, when they sold 333,340 shares at $15.00 per share.
Get notified when new Form 4 filings are submitted
| $23.00 |
| Discretionary |
| Apr 1, 2024 | DNTH | $0 | Other | 58,857 | $N/A | Discretionary |
| Apr 1, 2024 | DNTH | $0 | Other | 58,857 | $N/A | Discretionary |
| Sep 26, 2023 | DNTH | $394.5K | Purchase | 30,000 | $13.15 | Discretionary |
| Sep 19, 2023 | DNTH | $396.0K | Purchase | 30,000 | $13.20 | Discretionary |
| Sep 13, 2023 | DNTH | $110.2K | Purchase | 9,367 | $11.76 | Discretionary |
| Sep 12, 2023 | DNTH | $161.5K | Purchase | 14,887 | $10.85 | Discretionary |